Stockhub

BELLUS Health Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

27 July 2022

  • curprev 00:1800:18, 27 July 2022‎ Chris talk contribs‎ 412 bytes +412‎ Created page with "BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/BELLUS_Health_Inc.’